Category: Medicinal plants

Posted on

Chinese fungi and tea

I’m killing a few hours at Hong Kong International Airport, so I pick up the latest issue of China Today. There’s a number of really interesting articles, but two little snippets jumped out at me. The first is a short note on the Chinese Caterpillar Fungus, Cordyceps sinensis. No, I’d never heard of it either, but it turns out that it is important in Chinese traditional medicine, and that it has not been possible to grow it in the lab. Until just now that is, hence the note in the Sci-tech Info section announcing the possibility of mass-production.

The other really nifty piece of sino-information occurs in the opening section of an Around China piece on the Zhenyuan Yi-Hani-Lanu Autonomous County. It seems that this ancient tea-growing area, with its tea-dominated forests, boasts what is considered the oldest and largest tea plant in the world. At 25 metres tall, almost 3 metres in diameter and an alleged 2,700 years of age, it is apparently quite the tourist attraction, and “its fleshy, glossy leaves produce a strong and lasting flavour.”

Posted on

More on gorilla medicine

It’s wonderful what happens when a real expert gets stuck into a question. Back in November, Luigi briefly blogged a story about pharmaceutical researchers who derived some inspiration from gorillas and their liking for a particular plant. In the comments, Kathryn Garforth Mitchell wondered about the access and benefit sharing aspects of the story. Luigi, characteristically, had no idea, feared for the worst, and hoped he was wrong. Well, maybe his hopes were not in vain, because Kathryn has spent the past four months ferreting out the details and piecing most of the story together. The result is an illuminating series of posts that shows just how complex arrangements can be. I’m not going to link to all four of them; you should start at number one — Gorilla medicine: a complex web — and work your way through them.

One interesting point of direct relevance. Scientists in the US say that they may source the active compounds from plants grown locally in Nigeria or Ghana. This is very atypical of pharmaceutical arrangements, which usually involve discovering the active ingredient in a plant and then synthesizing it chemically. It is also, perhaps, the biggest source of confusion for those interested in access and benefit sharing of specifically agricultural products. While genes may be discovered in farmer varieties and wild relatives, the value of those genes never derives from the manufacture of the gene’s products.

Posted on

Ginkgo the new kiwi?

Ginkgo, much in demand in Asia and Europe as a herbal remedy, is now being grown commercially in New Zealand, according to this article in the NZ press. The dried leaves are currently being exported, but there are plans for more local value-adding.

Posted on

Biodiversity still valuable for medicines

Nature is still supplying more than two-thirds of all “new chemical entities” that end up approved as drugs, according to the third in a long-term series of studies by David Newman and Gordon Cragg. Their scientific study of drugs introduced between 1981 and mid 2006 is online here. The study also reveals that 2004 saw the lowest number of new drugs introduced since 1981. According to New Scientist magazine, which reports on the study:

“The dip was due in part to the international Convention on Biodiversity rules covering exploitation of natural resources, says Danna Leaman of the World Conservation Union’s medicinal plant specialist group. She says that the Convention, signed in 1992, has increased the bureaucracy and cost of getting people into the field to collect plants for drug discovery.”

The scientists and reporters conclude that diversity is a vital and extremely valuable resource in the search for blockbuster drugs. And so it is.

My real problem with this whole approach is that it fails to disentangle agricultural biodiversity, and as a result countries think that their agricultural diversity is going to produce the same pots of gold at the end of the rainbow. But while drug companies may discover their billion-dollar blockbusters in plants (and occasionally animals) they don’t harvest them directly. They mimic and alter the drugs and find ways to make them under their control. Agriculture is not like that. Genetic resources find their way into new varieties and breeds, which are then commercialized. But the amounts involved are nothing like those in the pharmaceutical world, and yet that’s the backdrop against which people discuss agricultural bio-piracy. Here’s hoping that the International Treaty on Plant Genetic Resources for Food and Agriculture does indeed ease access and share benefits, as it is intended to do, and that the flow of genetic material starts up again in earnest.

While we’re on the subject of lumping all biodiversity together, another academic study has produced a biodiversity map of the world. While a press release and a report or two mention ecosystem services, they don’t tell us to what extent the scientists examined either agricultural species or the genetic diversity within those species. And I have not yet been able to get to the scientific study to find out.